Studies with bromocriptine: III. Concomitant administration of caffeine to patients with idiopathic parkinsonism.
Caffeine was administered to six patients with idiopathic parkinsonism in an attempt to potentiate the therapeutic response of bromocriptine, a dopamine (DA) receptor agonist, by inhibition of phosphodiesterase. In a double-blind study at doses of 1,000 mg daily, caffeine failed to enhance the antiparkinsonian action of bromocriptine (40 mg daily) given concomitantly. Although effective in potentiating the action of levodopa and other agonists in animal models of parkinsonism, caffeine is inactive in parkinsonism in man.
D001971:Bromocriptine / Q000008:administration & dosage* / Q000627:therapeutic use; D002110:Caffeine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004873:Ergolines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010726:Phosphodiesterase Inhibitors
D004873:Ergolines; D010726:Phosphodiesterase Inhibitors; D001971:Bromocriptine; D002110:Caffeine